learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
Search
forLearn
5 / 801 resultslearn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn β-Glycyrrhetinic Acid
learn nonspecific group of Fibronectins
Research
5 / 505 results
research Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
TNF-alpha inhibitors can cause various immune-related skin issues.
research The Acne-treatment Potential of Cinnamomum Camphora Chvar. Borneol Essential Oil in Vitro and in Vivo
Borneol Essential Oil could be a natural and safe acne treatment.
research Analysis of hidradenitis suppurativa–linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages
The document concludes that certain mutations may contribute to the inflammation in hidradenitis suppurativa and suggests that targeting TNFα could be a treatment strategy.
research Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
research Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database
Some drugs used to treat inflammation may cause hair loss.
Community Join
5 / 1000+ results
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Why are there no FDA approved NSAA's yet?
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community Group Buy for MR antagonist finerenone
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
community 8 years of hair loss, turning 30 next month
The user has been dealing with hair loss for 10 years, worsened by psoriasis, and uses minoxidil and finasteride. They seek advice on managing psoriasis and hair loss, with suggestions to see a dermatologist, try different shampoos, and be patient.